These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 11212241)

  • 1. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
    Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
    Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
    Bailly C; Dassonneville L; Colson P; Houssier C; Fukasawa K; Nishimura S; Yoshinari T
    Cancer Res; 1999 Jun; 59(12):2853-60. PubMed ID: 10383146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
    Urasaki Y; Takebayashi Y; Pommier Y
    Cancer Res; 2000 Dec; 60(23):6577-80. PubMed ID: 11118036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
    Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
    Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
    J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
    Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
    Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.
    Fujimori A; Hoki Y; Popescu NC; Pommier Y
    Oncol Res; 1996; 8(7-8):295-301. PubMed ID: 8938793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.
    Tanizawa A; Pommier Y
    Cancer Res; 1992 Apr; 52(7):1848-54. PubMed ID: 1312902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
    J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines.
    Beidler DR; Chang JY; Zhou BS; Cheng YC
    Cancer Res; 1996 Jan; 56(2):345-53. PubMed ID: 8542590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
    Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
    Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
    Fujimori A; Gupta M; Hoki Y; Pommier Y
    Mol Pharmacol; 1996 Dec; 50(6):1472-8. PubMed ID: 8967967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
    Fujimori A; Harker WG; Kohlhagen G; Hoki Y; Pommier Y
    Cancer Res; 1995 Mar; 55(6):1339-46. PubMed ID: 7882333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
    Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
    Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
    Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
    Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
    Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.